Last Update 18 Mar 26

Fair value Increased 0.082%

ILMN: Future Returns Will Hinge On China Recovery And 2026 Tools Demand

Illumina's updated analyst price target sits slightly higher at about $136, with analysts citing firmer revenue and margin assumptions, a modestly higher discount rate, and supportive recent commentary on competitive pricing for whole genome sequencing consumables.

Analyst Commentary

Recent Street research on Illumina reflects a mix of optimism and caution, with several firms adjusting price targets and reassessing the setup for the next couple of years. For you as an investor, the key themes center on how competitive pricing, end market demand, and execution into 2026 could influence valuation and growth expectations.

Bullish Takeaways

Bullish analysts view Roche's announced $150 per genome duplex consumables price for its Xpandomer based nanopore sequencer as supportive for Illumina, since expectations had been for a lower figure and Illumina list pricing is cited at $200 per genome, with discounts referenced around $150 to $180.
Several bullish analysts have raised price targets, pointing to what they describe as recovering end markets and sector rotation that, in their view, set the stage for Illumina to participate in a broader life science tools trade into 2026.
Some research highlights that many companies in the tools space have already guided conservatively for 2026, which bullish analysts interpret as leaving room for upside if execution on revenue and margins tracks ahead of those soft expectations.
Survey work cited by one bullish group indicates healthy procedure and CapEx trends into 2026 and early recovery signs in China, which they see as supportive for Illumina's medium term growth profile if the company can execute against that demand.

Bearish Takeaways

Bearish analysts have lowered their price targets, signaling concern that the recent share move may already reflect a good portion of the Q4 and 2026 setup, which could limit upside if Illumina's results or guidance do not meet heightened expectations.
Some cautious views focus on the need for sustained execution in end markets and the risk that any slowdown in procedure volumes, CapEx, or China recovery could pressure Illumina's revenue growth and margin assumptions that are embedded in current targets.
There is also attention on broader sector risks, including potential changes to ACA and Medicare that could affect healthcare spending patterns, which bearish analysts flag as factors that may weigh on tools valuations, including Illumina, if they turn less supportive.
Even among firms that have raised targets, some maintain more neutral ratings and frame Illumina as a Hold, reflecting a view that while the setup for 2026 tools exposure has improved, execution and competitive dynamics still need to be proven out before assigning richer multiples.

What's in the News

Illumina is expected to appoint Eric Green, former NIH director, as chief medical officer, which signals a focus on clinical leadership and medical strategy (Endpoints News).
The company outlined earnings guidance for fiscal 2026, with expected total revenue of US$4.5b to US$4.6b, including a 1.5% to 2.0% contribution from the SomaLogic acquisition.
Illumina launched TruPath Genome, a whole genome offering priced at US$395 per genome that targets hard to sequence regions and aims to provide higher accuracy and throughput for genetic disease research.
Illumina announced a roadmap of NovaSeq X system updates over 18 months, targeting higher quality scores, increased output to up to 35b reads, and workflow flexibility for high throughput applications.
Reimbursement was granted by CMS for Illumina's TruSight Oncology Comprehensive test at US$2,989.55 under the Clinical Laboratory Fee Schedule, which creates a defined payment level for Medicare patients starting January 1, 2026.

Valuation Changes

The fair value estimate has risen slightly from $135.94 to $136.05, indicating a very modest upward revision in the intrinsic value.
The discount rate has moved up slightly from 7.99% to 8.07%, implying a slightly higher required return in the updated assumptions.
The revenue growth assumption has increased from 4.50% to 5.40%, reflecting a somewhat stronger outlook for top-line expansion in the model.
The net profit margin assumption has edged higher from 19.66% to 20.14%, pointing to a small change in expected profitability.
The future P/E multiple has been reduced from 24.38x to 22.97x, suggesting a somewhat lower valuation multiple applied to Illumina's expected earnings.

12 views

Key Takeaways

Expansion in clinical genomics and next-generation sequencing adoption is driving strong, recurring revenue growth and future earnings visibility.
Ongoing innovation, multiomics expansion, and operational efficiency are enhancing gross margins and creating new growth opportunities.
Persistent research budget constraints, regulatory risks in China, rising competition, commoditization, and clinical dependency threaten Illumina's revenue growth, margins, and market position.

Catalysts

About Illumina

Provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.What are the underlying business or industry changes driving this perspective?

Strong and resilient growth in clinical applications-especially oncology, genetic disease testing, and reproductive health-continues to expand as genomic technologies become the standard of care, supporting both recurring revenues from consumables and long-term earnings visibility.
Increasing adoption of next-generation sequencing for preventive healthcare and early disease detection is driving broader utilization of Illumina's platforms, particularly as clinical markets now represent over 60% of sequencing consumables, positioning the business for sustained volume and revenue growth.
Ongoing innovation-evidenced by successful launches like MiSeq i100 Plus and increasing uptake of NovaSeq X-lowers barriers for new customer segments, enhances platform performance, and supports higher gross margins as transitions accelerate, particularly in the clinical segment.
Strategic expansion into multiomics, notably the planned acquisition of SomaLogic and integration of proteomics capabilities, creates incremental growth opportunities by increasing the breadth of Illumina's data and platform offerings, contributing to future revenue and operating margin expansion.
Operational efficiencies, disciplined cost controls, and targeted share repurchases have already resulted in notable operating margin and EPS improvements, and further scaling-along with tax headwinds turning into tailwinds-sets the stage for continued net margin and earnings growth over the next several years.

Illumina Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Illumina's revenue will grow by 3.6% annually over the next 3 years.
Analysts assume that profit margins will shrink from 29.3% today to 18.4% in 3 years time.
Analysts expect earnings to reach $873.5 million (and earnings per share of $5.66) by about September 2028, down from $1.3 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $1.0 billion in earnings, and the most bearish expecting $715.5 million.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 22.2x on those 2028 earnings, up from 12.0x today. This future PE is lower than the current PE for the US Life Sciences industry at 29.3x.
Analysts expect the number of shares outstanding to decline by 3.09% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.53%, as per the Simply Wall St company report.

Illumina Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Heightened U.S. research funding uncertainty and ongoing NIH budget constraints are leading to persistent softness in the research end-market, significantly limiting instrument purchases and creating a negative long-term headwind for revenue growth and earnings diversification.
Increased export restrictions and regulatory uncertainties in China are causing a sustained decline in Chinese instrument and consumables revenue; management notes the situation is currently unsustainable, indicating elevated risk to international revenue streams and future top-line growth.
Intensifying competition, particularly from upcoming platforms like Roche's with faster turnaround times, poses the risk of price pressure, potential market share loss, and margin compression, especially as the market for high
and mid-throughput sequencing matures.
There is ongoing commoditization of next-generation sequencing (NGS) technology as well as a shift towards decentralized, benchtop sequencers like the MiSeq i100, which could lower barriers for competitors, shift purchasing patterns, and erode gross margins and operating leverage over time.
The company's dependence on continued strong growth in clinical applications carries risk; if clinical adoption or reimbursement slows, demand for sequencing platforms and consumables could weaken, leading to lower revenue growth and potential negative impact on earnings and margins, especially as clinical now makes up over 60% of consumables revenue.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $111.952 for Illumina based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $185.0, and the most bearish reporting a price target of just $75.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $4.8 billion, earnings will come to $873.5 million, and it would be trading on a PE ratio of 22.2x, assuming you use a discount rate of 7.5%.
Given the current share price of $98.22, the analyst price target of $111.95 is 12.3% higher. Despite analysts expecting the underlying buisness to decline, they seem to believe it's more valuable than what the market thinks.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Illumina?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

ILMN: Operational Progress Will Offset Ongoing China Exposure And Sector Uncertainties